129798-05-6

Upstream product

• 591-33-3 3-ethoxyacetanilide 
• 68-12-2 N,N-dimethyl-formamide 
• 621-33-0 m-phenetidine 
• 60-35-5 acetamide 

Downstream Products

• 745830-19-7 7-ethoxyquinoline-3-carbaldehyde 
• 1326718-03-9 C₁₉H₁₇NO₃ 
• 1326717-93-4 C₂₅H₂₂N₄O₃ 
• 1326717-83-2 C₂₅H₂₀N₄O₃ 
• 1352390-64-7 C₂₇H₂₄N₄O₄ 
• 1325757-34-3 C₂₀H₁₅BrClNO₂ 

Relevant academic research and scientific papers

Development of 5-Aminopyrazole-4-carboxamide-based Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy

Cryptosporidium is a leading cause of pediatric diarrhea worldwide. Currently, there is neither a vaccine nor a consistently effective drug available for this disease. Selective 5-aminopyrazole-4-carboxamide-based bumped-kinase inhibitors (BKIs) are effective in both in vitro and in vivo models of Cryptosporidium parvum. Potential cardiotoxicity in some BKIs led to the continued exploration of the 5-aminopyrazole-4-carboxamide scaffold to find safe and effective drug candidates for Cryptosporidium. A series of newly designed BKIs were tested for efficacy against C. parvum using in vitro and in vivo (mouse infection model) assays and safety issues. Compound 6 (BKI 1708) was found to be efficacious at 8 mg/kg dosed once daily (QD) for 5 days with no observable signs of toxicity up to 200 mg/kg dosed QD for 7 days. Compound 15 (BKI 1770) was found to be efficacious at 30 mg/kg dosed twice daily (BID) for 5 days with no observable signs of toxicity up to 300 mg/kg dosed QD for 7 days. Compounds 6 and 15 are promising preclinical leads for cryptosporidiosis therapy with acceptable safety parameters and efficacy in the mouse model of cryptosporidiosis.

Quinoline Based Monocarbonyl Curcumin Analogs as Potential Antifungal and Antioxidant Agents: Synthesis, Bioevaluation and Molecular Docking Study

In search for new fungicidal and free radical scavenging agents, we synthesized a focused library of 2-chloroquinoline based monocarbonyl analogs of curcumin (MACs). The synthesized MACs were evaluated for in vitro antifungal and antioxidant activity. The antifungal activity was evaluated against five different fungal strains such as Candida albicans, Fusarium oxysporum, Aspergillus flavus, Aspergillus niger, and Cryptococcus neoformans, respectively. Most of the synthesized MACs displayed promising antifungal activity compared to the standard drug Miconazole. Furthermore, molecular docking study on a crucial fungal enzyme sterol 14α-demethylase (CYP51) could provide insight into the plausible mechanism of antifungal activity. MACs were also screened for in vitro radical scavenging activity using butylated hydroxytoluene (BHT) as a standard. Almost all MACs exhibited better antioxidant activity compared to BHT.

REPLICATION PROTEIN A (RPA)-DNA INTERACTION INHIBITORS

This invention relates to RPA compounds or pharmaceutically acceptable salts thereof, and for the use of the compounds to treat cancer.

One-pot strategy for thiazole tethered 7-ethoxy quinoline hybrids: Synthesis and potential antimicrobial agents as dihydrofolate reductase (DHFR) inhibitors with molecular docking study

Over the world and especially the developing countries, one of the major threats to human health is antibiotic resistance due to antibiotics abuse. This challenge can be solved by discovering new targets and inhibitors. The current study involved synthesi

Structure-Guided Optimization of Replication Protein A (RPA)-DNA Interaction Inhibitors

Replication protein A (RPA) is the major human single stranded DNA (ssDNA)-binding protein, playing essential roles in DNA replication, repair, recombination, and DNA-damage response (DDR). Inhibition of RPA-DNA interactions represents a therapeutic strategy for cancer drug discovery and has great potential to provide single agent anticancer activity and to synergize with both common DNA damaging chemotherapeutics and newer targeted anticancer agents. In this letter, a new series of analogues based on our previously reported TDRL-551 (4) compound were designed to improve potency and physicochemical properties. Molecular docking studies guided molecular insights, and further SAR exploration led to the identification of a series of novel compounds with low micromolar RPA inhibitory activity, increased solubility, and excellent cellular up-take. Among a series of analogues, compounds 43, 44, 45, and 46 hold promise for further development of novel anticancer agents.

Synthesis, biological evaluation and computational study of new quinoline hybrids as antitubercular agent

Background: Tuberculosis is global health threat caused by infectious bacillus called Mycobacterium tuberculosis. To develop newer antitubercular agents against bacterial resistance, we have designed new quinoline derivatives 6a-6f and 7a-7f by molecular hybridization approach and evaluated for antitubercular, antioxidant and cytotoxicity studies along with molecular docking study. Methods: The designed molecules were synthesized by multi-step synthetic protocol and structures of compounds were confirmed by NMR, Mass and Elemental analysis. The synthesized derivatives were screened for antitubercular activity against Mycobacterium tuberculosis using Microplate Alamar Blue Assay (MABA). The antioxidant activity and cytotoxicity were also evaluated using 1,1-Dipheny-1-picrylhydrazyl (DPPH) radical scavenging and Sulforhodamine B (SRB) assay, respectively. The molecular docking studies were performed in Glide v5.6 (Schrodinger). Results: Among the synthesized derivatives, the compounds 6d and 7d displayed promising antitubercular activity, with MIC value of 18.27 and 15.00 μM respectively and are relatively nontoxic to HeLa cell line. The synthesized compounds were found to have potential antioxidant activities with IC50 range of 73.47-123.46 μM. The molecular docking study, physicochemical and pharmacokinetic properties prediction study suggested that the synthesized derivatives have potential for development of good drug candidate. Conclusion: Herein, we designed and synthesized a series of new quinoline pharmacophores appended with isoniazid and linezolid-like fragment as a promising strategy for the development of quinoline derivatives with potent biological activities.

MATERIALS AND METHOD FOR INHIBITING REPLICATION PROTEIN A AND USES THEREOF

Targeting uncontrolled cell proliferation and resistance to DNA damaging chemotherapeutics with at least one reagent has significant potential in cancer treatment. Replication Protein A, the eukaryotic single-strand (ss) DNA binding protein, is essential for genomic maintenance and stability via roles in both DNA replication and repair. Reported herein are small molecules that inhibit the in vitro, in vivo, and cellular ssDNA binding activity of RPA, thereby disrupting the eukaryotic cell cycle, inducing cytotoxicity and increasing the efficacy of chemotherapeutic agents damage DNA, and/or disrupt its replication and/or function. These results provide new insights into the mechanism of RPA-ssDNA interactions in chromosome maintenance and stability. This represents a molecularly targeted eukaryotic DNA binding inhibitor and demonstrates the utility of targeting a protein-DNA interaction as a means of studying the cell cycle and providing a therapeutic strategy for cancer treatment.

Synthesis and SAR of 2-aryl-3-aminomethylquinolines as agonists of the bile acid receptor TGR5

Optimization of a screening hit from uHTS led to the discovery of TGR5 agonist 32, which was shown to have activity in a rodent model for diabetes.

Quinoline inhibitors of hyaki and hyak3 kinases

This invention relates to novel quinoline inhibitors of hYAK1 and hYAK3 kinases and pharmaceutically acceptable salts, hydrates or solvates thereof, pharmaceutical compositions thereof, and methods of treatment of diseases in which an excessive amount of

Enantioselective synthesis of substituted 3-quinolyl alkanols and their application to asymmetric autocatalysis

Enantioenriched 3-quinolyl alkanols act as asymmetric autocatalysts in the addition of diisopropylzinc to the corresponding substituted quinoline-3-carbaldehydes, to afford themselves with an amplified enantiomeric excess (ee) of up to 97%.